Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Glavni avtor: | Flora, Sanzida Alam |
---|---|
Drugi avtorji: | Azam, Faruque |
Format: | Thesis |
Jezik: | English |
Izdano: |
Brac University
2024
|
Teme: | |
Online dostop: | http://hdl.handle.net/10361/23693 |
Podobne knjige/članki
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
od: Khan, Muidul Hasan
Izdano: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
od: Paul, Pulock
Izdano: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
od: Rahman, Tasnim
Izdano: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
od: Sorno, Rubina Haque
Izdano: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
od: Hoque, Ismoth Ara
Izdano: (2024)